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Gliomas are a group of brain tumors composed by cells that display a phenotype similar to glial 
cells. The heterogeneity of the different glial phenotypes is reflected in that of gliomas, which 
include tumors primarily composed of astrocytes, oligodendrocytes, choroid plexus cells or radial 
glia cells [1].  
Gliomas represent almost 80% of all primary brain tumors, they are still mostly incurable and 
related to high mortality: the most common glioma and the most aggressive form, Glioblastoma 
Multiforme (GBM), is fatal within two years from diagnosis in more than 70% of cases [2]. 
The low survival of patients affected by these tumors is a direct consequence of their location, 
mainly due to the extreme delicacy of the organ from which they originate (in fact, the brain 
undergoes significant damage simply from the pressure produced by the neoplastic growth), but 
also due to the scarce accessibility to tumor, which is hardly operable and unreachable by 
hydrophilic molecules/macromolecules through to the blood-brain barrier (BBB), hindering the 
use of many of the most biologically active drugs [3]. 
One peculiarity of gliomas is that, despite the high invasiveness of their most malignant forms, 
they are usually not prone to metastasize, and only a small percentage (between 0.2% and 0.5%) 
give rise to metastasis outside the brain [4]. This fact can be partially explained by the low survival 
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of patients, which does not allow the acquisition of long-range migrating abilities by a mere 
deprivation of time. However, other causes contribute to this feature, such as the tightly 
regulated interchange between brain and blood stream by BBB, which avoids extravasation of 
cells, and the recently discovered lymphatic system of the brain, mainly managed by glial cells 
[5]. Another important reason is linked to the composition of the brain extracellular matrix 
(ECM), which lacks of the major glycoproteins, such as collagen and fibronectin, and for this 
reason is more permissive than other organs [6]. In fact, glioma cells are able to migrate in their 
native parenchyma, but given the absence of selective pressure, they rarely acquire the ability to 
engraft and invade organs shielded by connective matrix [7]. 
Since glioma progression rarely implies metastatization, which is an highly selective process [8], 
and is located in a relatively permissive environment, it is reasonable to hypothesize that glioma 
cells are subjected to a minor selection and therefore glioma progression can be easier for a 
transformed cell than the progression of other tumors. This may reflect and explain glioma intra-
tumoral heterogeneity. 
Glioma Heterogeneity 
In general, the heterogeneity of tumors consist of inter-tumoral and intra-tumoral heterogeneity 
[9]. Inter-tumoral heterogeneity refers to the differences between tumors from distinct patients, 
while intra-tumoral-heterogeneity refers to the phenotypical and genomic variations found in 
different cells within the same tumor. Both inter-tumor and intra-tumor heterogeneity are 




The inter-tumoral heterogeneity of gliomas has been historically tackled by searching an efficient 
classification for these tumors. This interest is primarily clinical and arises from the necessity of 
predicting the outcome of gliomas, which may be very different [2], and therefore guide clinical 
choices due to different risk-benefit ratios. 
The first type of glioma classification is based on histo-pathological analysis, and evaluates the 
tumor histology as well as the differentiation level of the tumor composing cells. This 
classification is regulated by the World Health Organization (WHO), which defined glioma 
subclasses and, over time, have been refined thanks to new knowledge on the subject. In the first 
edition of the classification, published in 1979, gliomas were classified by using parameters 
concerning the sole appearance of the tissue: according to this classification, gliomas are divided 
into astrocytomas, oligodendrogliomas or oligoastrocytomas, alluding to the type of glial cell they 
most resemble (Figure 1) [11]. 
 




This initial approach was mainly due to the analytical possibilities at the time, since microscopy 
was the most powerful technique to retrieve qualitative information from tumor biopsies [12, 
13]. However, this approach is based on the rationale  that different tumors originate from 
distinct cell types [14]. This view is mostly accepted but in the past decades it has been refined 
and it is still debated, because even if cell lineage has a strong impact on tumor physiology [15], 
some lineages are more distinctive than others. In hematopoietic malignancies, for example, 
tumor biology is strongly related to their cell of origin [16, 17], but in other cases, such as gliomas, 
the recognition of cell of origin is far from univocal. The first hypothesis on the origin of gliomas 
was that they originate from mature glial cells that during tumor progression undergo a process 
of de-differentiation [18], but more recent stronger evidences suggest that staminal or 
progenitor populations are the most likely cells of origin of gliomas [19-22]. However, the 
complexity of neural stem cell lineages in the brain [23] makes the recognition of glioma cell 
lineage even more elusive. Gliomas developed in distinct brain regions can share molecular 
signatures even if histologically indistinguishable [24], and In the case of ependymomas, distinct 
tumor signatures resemble those of neural progenitor cells in the corresponding regions of 
central nervous system [25]. Taken together, these evidences suggest that glioma heterogeneity 
can be due to their derivation from different site-specific cell populations. Other evidences on 
the impact of cell of origin in the glioma biology come from mouse models: molecular lesions can 
be driven in restricted cell populations of recombinant mice by the use of lineage-specific 
promoters to drive the expression of oncogenes, Cre recombinase [26], or TVA receptor to utilize 
the RCAS-TVA system [27]. These studies defined that immature populations of brain, but not 
mature glial cells, are able to give rise to tumors after first hits of gliomagenesis such as Ras and 
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Akt activation [20], or p53, Nf1, Pten [21] and Ink4a-Arf [22] inactivation alone. Animal models 
also highlighted some discrepancies: Although vast majority of studies identifies radial-glia like 
neural stem cells (NSCs) as progenitors for most gliomas, some studies identified other 
populations, such as reactive astrocytes for PDGF and NF1 driven glioblastomas [28], and several 
reports suggested that gliomas can arise from oligodendrocyte precursor cells (OPCs)  [29-31]. In 
particular, two works studied glioblastomas driven by the same molecular lesions in different 
cells, and concluded that both suppression of p53, Nf1 and Pten [32] , and overexpression of 
PDGF-B [33] in OPCs are able to induce glioblastomas, but they belong to different subclasses if 
compared to glioblastomas derived from Nestin+ NSCs.  Strikingly, under extreme condition such 
as overexpression of Polyoma virus middle T antigen, even mature astrocytes can give rise to 
mixed astrocytic and oligodendrocytic gliomas [34]. Interestingly, this last study showed that 
glioma cell lineages are plastic enough to be generated by a single cell type. Consistent with this 
evidence, other researchers demonstrated that OPCs be cell of origin of both astrocytoma and 
oligodendroglioma in an oncogene-dependent manner: overexpression of PDGF-B leads to 
oligodendroglial tumors, while combined overexpression of KRAS and AKT generates gliomas 
displaying astrocytic histology [35]. This result shows that molecular lesions can be dominant to 
cell of origin in the determination of glioma phenotype. 
Even if lots of evidence show that glioma inter-tumoral heterogeneity is a consequence of the 
cell of origin biology, its recognition is far from being easy, and other factors such as mutations 
can have an equal or even stronger impact on their biology [19, 36]. An alternative approach to 
obtain insights on the inter-tumoral heterogeneity of gliomas and is to classify them by their 
mutations and/or their gene expression: In particular, gene expression profile can give integrated 
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information about cell of origin and genomic lesions. Using this paradigm, Glioblastomas have 
been clustered in base of molecular lesions, focusing on the repercussion of unregulated genes 
on known signaling pathways. In this way, it is possible to identify three subgroups characterized 
by (1) an increased signaling of EGFR, (2) an increased signaling of PDGFRα, or (3) a decreased 
signaling of NF1 [37]. 
 
A first  transcriptomic clustering of glioblastomas was performed by k-means clustering of 76 
GBM samples, and identified 3 subgroups, named them Proneural, Proliferative, and 
Mesenchymal by recognizing the dominant features of the gene list that characterize each 
subclass. Proneural subclass display a better prognosis than the other two, and interestingly, 
most recurrences shift to the mesenchymal subtype, the most aggressive. This classification 
proved its prognostic value correctly predicting outcome in patients depending on their 
belonging to the three subclasses [38]. Few years later, a similar analysis defined one of the most 
important subclassifications of glioblastomas, comparing the transcriptome of 433 Glioblastomas 
obtained from The Cancer Genome Atlas (TCGA). Differential gene expression analysis revealed 
840 modulated genes able to divide this single WHO class in four subclasses, termed classical, 
neural, proneural and mesenchymal [39]. Consistent with the other clustering, neural and 
proneural tumors have a better prognosis than classical and mesenchymal glioblastomas and 
furthermore, these subtypes display different responses to treatment: proneural tumors are less 
aggressive but also less responsive to strong therapies compared to classical and mesenchymal 
tumors. Therefore, this classification can accurately guide the therapy of patients. 
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The importance of genomic and transcriptomic classifications, as well as the interest on this 
approach, started to grew since this classification and, in 2016, WHO classified tumors of the 
central nervous system considering both histopathological characteristics and genomic 
characteristics. The categories are then remodeled and more objective then the previous 
classifications. 
Intra-tumoral heterogeneity 
Cells which compose the same tumor can be genetically and/or phenotypically different each 
other [40, 41]. This phenomenon is called intra-tumoral heterogeneity, and it has shown to be 
the main cause of the partial response to therapies and the development of recurrences [42]. For 
all these reasons, intra-tumoral heterogeneity received a lot of interest in cancer research. 
Gliomas are tumors characterized by a high intra-tumoral heterogeneity [43-45]. Multi-region 
sampling of human glioblastomas revealed that different regions of same tumor can belong to 
different molecular classes [46], and more strikingly single-cell RNA sequencing confirmed that 
most Glioblastomas are composed by cancer cells that individually belong to all the four 
molecular GBM subclasses. These data also demonstrate that cancer cells composing same 
glioma can be different each other as much as different gliomas. 
While in principle inter-tumoral heterogeneity could be explained by the existence of different 
cells of origin, intra-tumoral differences are deeply correlated to tumor progression and 
evolution. Since 1976, it has been proposed that tumor evolution imply multiple branching steps 
leading to the emergence of subclones which can expand and sometimes eradicate or sometimes 
coexist with other clones, generating a dynamic and heterogeneous population of tumor cells 
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[47]. This model is ongoing widely accepted, and genomic analyses of heterogenic tumors reveal 
that in many cases it is possible to reconstruct the evolutive process of tumor progression, and 
find the single branching points leading to the intra-tumoral heterogeneity [48-50] . This 
approach also lead to the evidence that metastasis, usually phenotypically different from the bulk 
primary tumor site, derive from a clone which already diverged and expanded in the primary 
tumor site [49]. 
Intra-tumoral heterogeneity can be addressed by clonal tracing the tumor cells by the use of 
genetic barcoding. 
Genetic barcoding 
Genetic barcodes (or DNA barcodes) are short sequences of DNA in the genome of a cell that can 
univocally tag the cell itself and consequentially its whole progeny. Genetic barcodes can be 
either natural or synthetic sequences. 
Natural DNA barcodes are usually short stretches of coding sequence that are used to identify 
different species in heterogeneous populations. The discovery and use of natural barcodes is not 
trivial: to be useful, a genetic barcode needs to be variable enough through evolution to make 
species recognizable, but in the same time stable enough to be retrievable in a big group of 
organisms. Examples of successful barcodes are Cytocrome C Oxidase I for animals [51], and 
chloroplast DNA for various plant species [52], but the most successful and used natural DNA 
barcode is a region of ribosomal 16S sequence, shared by almost all prokaryotes, that can identify 
a very large set of bacteria and archaea species [53], making it extremely useful for ecological 
[54], and medical microbiome studies [55]. 
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On the other hand, synthetic DNA barcodes are synthetic DNA sequences that can be designed 
to be as heterogenic as possible, but need to be integrated in the genome of the cells in order to 
label them. First implementations of this approach used microarray-based recognition of 
barcodes, and consequently barcodes were designed as 100 bp long sequences to allow efficient 
hybridization [56]. This method made possible to study clonal dynamics of T cell lineage [56, 57]. 
However, it was extremely labor-intensive and implied the use of mixtures of pre-defined DNA 
sequences, making it difficult to scale up the number of different barcodes. For this reason, DNA 
barcoding did not spread much before the establishment of Next Generation Sequencing (NGS) 
techniques, which allow the parallel sequencing of billions short sequences [58]. Thanks to NGS, 
barcodes can be identified and quantified without any prior information, making the use of high 
complexity barcode libraries more practical. Since then, synthetic barcodes become shorter, 
usually not much longer than 25 nucleotides, given that a completely degenerated sequence of 
this length can have more than 1015 possible forms and thus can be useful for the study of 
extremely heterogeneous populations [59]. Genetic barcodes have been extensively used to 
track the clonal dynamics of hematopoietic system [60, 61], and cancer [62-65].  
Synthetic barcodes design is highly permissive, and indeed lots of variations have been 
developed. For example, modular barcodes containing multiple CRISPR/Cas9 target sites have 
been designed to progressively accumulate mutations during time enabling the tracing of 
divergent populations in vivo [66, 67], while Brainbow mouse-inspired [68] approaches led to the 
design of single modular barcoding loci that can be integrated in-vitro or in-vivo and generate 
more than 104 [69] or 109 [70] different sequences after Cre-Lox recombination, and can be 




Rationale and Aim of the thesis 
The clonal dynamics of glioma progression is not fully understood. Most of the information about 
tumor progression is derived by post-analysis of already progressed tumors and reconstruction 
of clonal evolution from already progressed tumors.  
The model of gliomagenesis developed in our lab is induced by the overexpression of PDGF-B, a 
known oncogene typical of glioblastomas, in embryonic progenitor cells by in vivo injection of 
retroviral particles in telencephalic ventricles of mice embryos at E14 stage. Transduced cells 
grow and generate neoplasms in mice brains that undergo tumor progression and, after a first 
low-grade stage, they gain malignancy and resemble human Glioblastoma [71]. Since in this 
model gliomagenesis is induced by retroviral-mediated gene transfer, is particularly suitable for 
clonal tracing using genetic barcodes. The oncogenic retrovirus can be modified inserting a 
degenerated barcode sequence generating a viral library that can, in a single step, mimic the 
same first hit of gliomagenesis in multiple cells and label each transformed cell, allowing the 
clonal tracing of each cell composing gliomas.  
The aim of this thesis is to highjack this mouse model to directly analyze the clonal dynamics of 
glioma progression and investigate eventual clonal bottlenecks and relation between clones at 






Barcoding library production and validation 
General design and plasmid library construction 
I decided to insert the barcode (BC) sequences in the expressed retroviral region containing 
PDGF-B and GFP (Figure 2A). BCs will be then integrated in the cell genome , but also transcribed, 
thus giving the opportunity to recover information either trough genomic DNA extraction or RNA 
extraction and retro-transcription. Given that the BC insertion in the vector must be as efficient 
as possible, I initially modified the vector by inserting, via NotI cloning, a landing cassette 
containing a stuffer DNA sequence flanked by two short regions. After the final step of library 
production these regions will be flanking the BC and will be used to amplify them by an efficient 
and specific PCR. 
 
Figure 2: Barcoding vector design. A: schematic view of the tumorigenic vector and barcode insertion region, highlighted 
by the NotI site. B: probability to label two cells with the same barcode derived from silico simulation of infections using 




To define the flanking regions sequences I generated three pairs of synthetic primers, 
complementary to a random in-silico generated template. Primers were tested on murine 
genomic DNA and cDNA derived from murine NPCs and PDGF-B driven tumors. One pair resulted 
to be completely orthogonal to the biological samples and was chosen for the vector design 
(Figure 3). 
 
Figure 3: Synthetic primers specificity test. Although their specificity had already been tested bioinformatically by BLAST 
algorithm, they were used in qPCR on murine samples in order to validate them empirically. Primers for the housekeeping gene 
l41 were used as a positive control  
 
Barcode sequences were obtained by organic synthesis of 22-nt long degenerated 
oligonucleotides, consisting of 11 "B" (T, C or G) and "H" (A, T or C) repeats. This degenerated 




In order to minimize the probability to tag different cells with the same barcode, it is necessary 
to generate a sufficiently complex barcoding library, harboring enough different barcode 
sequences. In-silico simulation revealed that to keep this probability under 5% or 1%, the library 
must harbor respectively around 104 or 105 different sequences (Figure 2B), which is so my target 
complexity. 
Barcode sequences were inserted in the viral vector by Gibson Assembly and 150 ng of the 
reaction product (about 1010 molecules) was electroporated in high-efficiency E coli cells. In order 
to avoid statistical drifts and inequalities in library composition, bacteria were grown in high 
volume (5 l) of LB and their growth was stopped in exponential phase. I retrieved 700 µg of 
plasmid DNA library, that was initially sequenced by Sanger sequencing to have a first estimate 
of the heterogeneity of the barcode region: the electropherogram obtained confirms the 
presence of a degenerated 22-nt long stretch (Figure 4). 
 
Figure 4:Sanger sequencing of the barcode region. Consistently with the imposed barcode pattern, all the 22 positions of 
the barcode contain three peaks, revealing a degenerated sequence.    
 
Plasmid library validation 
NGS sequencing of the plasmid preparation was performed to better evaluate the 
heterogeneity of the library and to set up the BC sequencing protocol. I chose to start using Ion 
torrent platform because it allows relatively low depth (about 5·105 reads) sequencing, perfect 
for the validation of a single sample. Two independent sequencing libraries were generated by 
PCR and BCs were retrieved by bioinformatic alignment of the viral backbone. I analyzed the 




Figure 5: Sequence logo generated from all barcode sequences retrieved from NGS sequencing. The pattern consisting of 
BH repetitions is recognizable 
 
All the different BCs were clustered basing on Hamming distance: as expected from in-silico 
simulations, barcodes have a mean Hamming distance of 14 nucleotides, and a clearly different 
population of smaller Hamming distances is recognizable, mostly due to PCR and NGS errors: this 
first observation helped me to set the threshold to distinguish genuinely different barcodes from 
PCR/NGS artifacts. 
 
Figure 6: distribution of Hamming distances between barcode sequences. A distinct subpopulation of low distances is 
recognizable and can be explained by PCR mutations or NGS errors 
 
Once clustered, BCs having Hamming distance >5 were counted in both subsampling of the 
plasmid library. 2*104 different sequences have been found in each sequencing, and strikingly 
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only 138 sequences are shared by the two, leading to an estimate of more than 106 different 
sequences in the total library. 
Retroviral library construction and in vitro validation 
Once the plasmid library was validated, high titer (106 infecting particles/ml) library of 
retroviral vectors was generated by transfecting the plasmid library into packaging cells. Before 
using this library for in vivo experiments, I had to perform preliminary in vitro tests to check that: 
1. The viral library is highly complex and each barcode sequence is equally 
represented, and so able to label each infected cell with a different barcode (barcoding 
efficiency). 
2. Each infected cell integrates just one of the two retroviral chromosomes and 
contains just one barcode sequence (unique labeling). 
Barcoding efficiency 
I performed 5 independent infections of NIH-3T3 cells using the viral library at low multiplicity 
of infection (MOI). 12h after the infection cells were detached and divided in two samples: 10% 
of them was plated at low density in glass coverslip to estimate, after some cell divisions, the 
number of infected cells by epifluorescence microscopy thanks to the GFP expression. The 
remaining 90% of them was plated and collected after 3 cell divisions, the genomic DNA was 
extracted and amplified by PCR to generate 5 Ion Torrent sequencing libraries. 
The number of GPF positive clones estimated by fluorescence microscopy nicely corresponds 
to the number of different barcode sequences retrieved from Ion torrent sequencing, and no 
particular imbalance in barcode composition was found. 
I used the same data to estimate the viral library complexity. I counted, for each sequence, 
the number of different infections in which it was detected, and I compared the experimental 
data to different simulations based on different defined complexities: by using as parameters the 
frequencies of barcodes found in 1, 2, or 3 independent infections I have a solid estimate of the 




Figure 7: barcoding efficiency validation and heterogeneity estimation. A: number of estimated infected cells by 
fluorescence microscopy compared to the number of detected barcode sequences. B: experimental data about barcode 
distribution between the 5 independent infections is compared to viral complexity simulations and consistently indicates the 
presence of 1.5+105 different sequences. 
 
Unique labeling 
To observe the multiplicity of barcode integration in uniquely infected cells I infected NIH-3T3 
cells as in the previously described experiment and obtained clonal colonies of GFP positive cells 
by limit dilution cloning. I extracted the DNA from 10 clones and analyzed the barcode region by 
Sanger sequencing: each clone harbored a single barcode sequence (Figure 8:), suggesting that 




Figure 8: sanger sequencing of barcodes from genomic DNA of clonal progeny of infected cells. Each clone harbors a single 
barcode sequence. 
 
Tumoral progression in primary tumors 
Embryonic infections 
I then proceeded with the in vivo experiment: the retroviral library was injected into the 
telencephalic ventricles of E14 murine embryos. The infection is not lethal for the mice, which 
complete che development and are born. It has already been shown that at this stage the PDGF-
B overexpression is sufficient to induce neoplasms in the brain that undergo tumor progression 
and pass through a low malignancy stage, in which they are composed by cells that are not 
tumorigenic if orthotopically transplanted in syngeneic mice (low grade gliomas), and by time 
reach a more malignant stage gaining the ability to give rise to secondary tumors (high grade 
gliomas). 
I collected the brains from 7 mice embryos at stage E18, 4 days after the viral infection, to 
analyze the starting heterogeneity of the transduced cells. Given the low amount of GFP positive 
cells I decided to extract the genomic DNA from all the lysed brain. The barcode region was 
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amplified and sequenced by pooled Illumina sequencing as described in materials and methods. 
For each embryo, I generated 3 independent sequencing libraries, in order to normalize the 
possible inequalities due to PCR amplification and to estimate the sample complexity by studying 
the amount of barcodes shared by different subsampling. The initial amount of in vitro infected 
cells is 20±5·103 (Figure 9). 
 
 
Figure 9: Barcode sequencing of embryonic brains. Each embryo contains evenly distributed barcodes that can be estimated 





Progression from low to high grade gliomas 
I then dissected tumor tissue from the brain of mice harboring low-grade tumors. GFP positive 
population were enriched by FACS sorting and DNA was extracted from sorted cells. I decided to 
generate 3 sequencing libraries from each low grade glioma, as I did for the injected embryos. 
NGS sequencing reveals that even in earlier stages of glioma progression the initial population 
goes through a strong bottleneck: tumors harbor hundreds or even tens of different barcodes, 
suggesting that just a small percentage of transduced cells had the ability to reach the low-grade 
tumoral stage. Interestingly, the distribution of clones in the total tumoral mass appears to be 
quite homogeneous in most tumors, but some clones are bigger and in all the cases about half of 
the total mass is composed at most by the ten bigger clones, while the other half tumoral mass 
is usually composed by tens or hundreds smaller clones (Figure 10).  
 
Figure 10 :clonal composition of low-grade tumors. Clones are represented from bigger to  smaller. 
 
High-grade tumors, on the other hand, are characterized by a much lower clonal 
heterogeneity: each tumor contains on average 20 total clones, and more strikingly one or two 
main clones represent the main percentage of tumor mass. By this clonal analysis, I can also 
divide the High grade stage into 2 categories: tumors retrieved until 120 from embryonic 
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transduction are usually oligoclonal, while later tumors are mainly bi-clonal or even monoclonal 
(Figure 11). 
These data suggest that the tumoral progression, from the first molecular lesion to the last 
high-grade stage, is very unlikely. Given the number of initially transduced cell and the number 
of clones composing High-grade gliomas. This probability can be estimated as 10-4. A model with 
such probability imply that in a consistent proportion of cases not even a single clone manages 
to gain full malignancy. However, The penetrance of PDGF-B transduction is 100%. This evidence 
suggest that this estimate is the lower limit of the real probability of glioma progression, and 
other phenomena, like internal competition of clones, can explain the low amount of clones in 
full-blown gliomas. 
 
Figure 11: clonal representation of high-grade gliomas, divided by the time of onset. Clones are represented from bigger to 
smaller. 
 
To better understand the clonal dynamics of glioma progression, I studied the relation 
between clonal heterogeneity of gliomas and their time of onset, which can be considered the 
time of tumoral progression.  The clonal complexity of gliomas dramatically decrease over time: 
If the probability of clone loss is equal in the tumoral progression, the expected rate is an inverse 
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exponential. When plotted in a logarithmic scale, however, the number of clones shows a 
statistically significant, non linear correlation more than exponential decrease over time (Pearson 
correlation = -0.79; p<10-5, R2 = 0.63) , suggesting that during earlier stages of glioma progression 
clones are more prone to disappear and become more stable in later stages. This may be the 
result of the rising number of cells in each clone, but may suggest that glioma cells gain of 
malignancy make them stronger and less prone to be eradicated by the host. Interestingly, even 
if not clearly recognizable, the clonal purification rate in the gliomas is continuous and no main 
bottlenecks are discernable in a particular timeframe (Figure 12 A). 
A finer estimate of clonal heterogeneity can be made by Shannon-Weiner H' index, which 
integrates both number of clones and their relative distributions. This index shows a strong 
exponential fit with the time of tumoral progression (Pearson correlation = -0.96; p<10-5 R2 = 0.92), 
suggesting that even if clones are progressively more stable in gliomas, their relative differences 
keep exacerbating with a constant rate until the most malignant clone prevails. 
 
Figure 12: Clonal heterogeneity of gliomas during tumoral progression. Each dot represents a tumor or, in case of time 0, 
infected embryonic brains. A) The estimated number of clones in each tumor. B) The global heterogeneity estimated by 
Shannon-Weiner H' index. 
 
Acutely dissociated cells derived from glioma masses are able to give rise to secondary tumors 
in a onset time-dependent manner. Tumors progressed more than 70 days resemble high-grade 
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gliomas but they are not invariantly tumorigenic if orthotopically transplanted in syngeneic mice.  
0 out of 2 oligoclonal tumors progressed between 70 and 120 days gave rise to secondary tumors 
(Figure 13 A), while 4 out of 5 clonally homogeneous tumors (progressed more than 120 days) 
gave rise to clonally consistent secondary tumors. Two of them are monoclonal, and their 
secondary tumors contain only the parental clone as expected (Figure 13 C). The other two are 
composed by at least two clones, and in one case the clones are evenly balanced. Strikingly, all 
secondary tumors are composed by the same single parental clone (Figure 13 B). This is an 
evidence that high-grade gliomas can contain "passenger" clones, which are not able to engraft 






Figure 13. Transplantation assays of cells derived from primary tumors. A: Tumors progressed more than 70 and less than 




Tumor progression of in vitro transduced neural progenitor cells 
I then investigated the clonal dynamics also in an alternative induction of gliomagenesis, in which 
neural progenitor cells are explanted from E14 mice embryo and infected in vivo 2 hours after 
dissociation. After few doublings cells are transplanted in the brain of adult immunocompetent 
mice and gain malignancy giving rise to tumorigenic gliomas. Such model can be useful to analyze 
tumoral progression of same pools of early-transformed cells. 
4 independent pools of NPCs were infected at low MOI 2 hours after explant and dissociation. 
Each pool was transplanted in at least two mice and, after glioma development, tumoral masses 
were retrieved, sequenced and compared to the initial pool of transformed cells. Interestingly, 
the clonal architecture of these tumors is similar to that of the high-grade embryonic gliomas, 
suggesting that the two models are subjected to similar clonal dynamics. Some clones are among 
the most represented in different tumors derived from the same parental NPCs, and in one case 
(infection 1) 3 out of 4 tumors are composed by the same principal clone (Figure 14). This result 
suggest that some divergences in the first stages of glioma progression can strongly, but not 





Figure 14: clonal representation of infected NPCs at day of transplantation and derived tumors. Clones are represented from 
bigger to lower.  
 
Also in this case, the loss of clones is faster than exponential during tumor progression. Tumors 
start from one order of magnitude less clones than embryonic tumors, but they show an equal, 
shifted kinetics (Figure 15 A). Their overall heterogeneity, on the other hand, decreases with the 





Figure 15: Clonal heterogeneity of gliomas during tumoral progression in the two models. Each dot represents a tumor or, in 
case of time 0, infected embryonic brains or infected NPCs at day of transplant. A) The estimated number of clones in each 
tumor. B) The global heterogeneity estimated by Shannon-Weiner H' index. 
 
Glioma progression in immunodeficient mouse 
Recently published data from our laboratory [72] demonstrated that although low-grade 
glioma cells are not able to engraft in immunocompetent animals, they can grow and give rise to 
secondary tumors when transplanted in immunodeficient mice. Strikingly, cells continue tumor 
progression even in this model, and in fact, secondary tumors gain the ability to engraft also in 
immunocompetent mice. I used this knowledge to observe how the same pool of low-grade 
gliomas undergo tumor progression in independent mice.  
GFP-positive cells from a low-grade glioma were transplanted in 4 NOD-SCID mice and 2 C57-
bl6 mice as control, and part of them was used to sequence the barcodes of primary tumor. The 
low-grade glioma cells did not engraft in C57-bl6 mice, but generated secondary tumors in 3 out 
of 4 NOD-SCID mice. DNA from all the secondary tumors was extracted and sequenced, and cells 
from 2 secondary tumors were injected in immunocompetent mice. DNA from 3 tertiary tumors 
was collected and all the samples were sequenced using Illumina platform. 
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Sequencing data is shown in Figure 16. Each secondary tumor is composed by one major clone 
that represents more than half of total mass, one or two intermediate clones and some less 
proliferated clones. By this point of view, progression in immunocompetent mice resembles the 
progression observed in primary tumors, leading to oligoclonal high-grade tumors. An interesting 
finding is the agreement among the engrafted clones: although the main clone is different among 
independent secondary tumors, they derive from just 5 primary clones, which are probably more 
prone to engraft and keep gaining malignity. 2 of the clones are visible in each secondary tumor, 
2 are shared between 2 secondary tumors while the fifth is detectable in just a secondary tumor. 
A similar concordance, combined with the fact that other clones of equal size have not been able 
to attract in any animal suggests that already in early stages of tumor progression some clones 
are partially predetermined to give rise to secondary tumors, and so are more malignant than 
the others. 
This experiment provides also other evidences. Since the same number of cells was 
transplanted in mice for primary and secondary tumor induction, and clones engrafted in tertiary 
tumors were a consistent proportion of the initial low-grade tumors, therefore amount of 
injected cells belonging to particular clones is often similar, although the engrafting efficiency in 
immunocompetent mice is strikingly different. This finding highlights that tumoral progression is 
not simply due to preferential expansion of intrinsically more malignant clones, but that clones 
qualitatively change and become more aggressive. This evidence supports the idea of tumor 
progression as a gradual gain of malignancy opposed to the idea of a complete early divergence 









Studying the clonal heterogeneity of gliomas can help to estimate how many different 
populations compose them and their relation over time. This information is extremely important 
in the evaluation of target-specific therapies because can suggest how likely it can be shared 
between all tumor cells. 
The experimental design that I set up allows the clonal analysis of gliomas in different stages 
of tumor progression. Our data suggest that the entire tumor progression is a very unlikely 
process and implies strong bottlenecks in the initial pool of thousands transformed cells. This also 
suggest that even a molecular lesion like the overexpression of PDGF-B, already known to 
invariantly induce gliomas, is not the main event in gliomagenesis and other critical mutations 
are still needed for the full malignancy. During tumor progression clones undergo a dramatic 
selection, and interestingly their probability of tumoral progression is not fixed but continuously 
increase over time. Most likely internal competition is the main responsible of the progressive 
loss of clonal heterogeneity in later stages of progression, a time frame in which complete loss of 
clones is always less probable. 
Observing same pools of unprogressed cells undergoing glioma progression in parallel ways 
highlighted the stochastic nature of tumoral progression, thus uncovering that partial 
predetermination is possible even in first steps of gliomagenesis: in fact, some clones separated 
few days from transformation independently became the most represented clones in different 
tumors. Similarly, when tumor progression is split and low grade clones give rise to higher grade 
tumors in distinct immunocompetent mice, this partial predetermination shows up more clearly. 
The concordance seen in the clonal composition of secondary tumors suggest that some clones 
are more progressed than others and can more easily go through final progression steps in which 






Materials and Methods 
Cellular Biology 
Cell lines and culture media 
Primary cultures of dissociated tumor cells were grown in Matrigel-coated flasks and using a 
medium designed for the culture of neural stem cells, composed by High glucose DMEM 
(Invitrogen), F12 (Invitrogen), 1% B27 (Invitrogen), 0.01% bFGF, 0.01% EGF (PreProTech). 
NIH-3T3 cells were grown in DMEM supplemented with 10% Fetal Bovine Serum (FBS) 
Cell cultures 
Cells were grown in incubator at 37°C and 5% CO2. Adherent cells grow on the bottom of the 
plate forming a monolayer and, when they reached confluence, they were detached using 
Tripsin-EDTA (Gibco), which was then neutralized by DMEM containing FBS 10%. Neutralized 
medium was then removed by centrifugation and cells were suspended in their medium and 
plated. 
Retroviral particles production 
Replication-defective retroviral supernatants were prepared by transiently transfecting 
plasmid libraries into Phoenix packaging cells, which constitutively express the necessary 
retroviral proteins and when transfected with constructs containing retroviral LTR (Long Terminal 
Repeat) and Ψ sequences they are able to encapsulate them in retroviral particles [73]. 
Cell supernatant was collected after 48 and 72h after transfection and the particles were 




To determine the viral titer, low amount of virus particles was used to infect NIH-3T3 cells, 
plated on coverslips. 48h after infection, reporter-positive clones were counted under 
epifluorescence microscope. 
Molecular Biology 
DNA digestion using Restriction Enzymes 
Restriction enzymes were used for molecular cloning and to validate plasmid sequences. In 
every case digestion were carried 2h at optimal enzyme temperature using a thermoblock. The 
amount of used enzyme is 3 units/µg of DNA. Restriction Enzymes were purchased by New 
England Biolabs or Promega. 
Fragment purification or visualization were performed by agarose gel electrophoresis, using 
1% or 2% agarose. Agarose Gels were analyzed under UV or blue light and, in case of fragment 
purification, bands were excised and extracted using Qiagen Gel Extraction kit, using 
manufacturer’s protocol.  
Subcloning efficiency competent cells Transformation 
Non-heterogeneous vectors and small-scale tests were amplified by subcloning efficiency E. 
coli cells (Thermo Fisher). Cells were transformed by heat-shock by keeping them 45’’ at 42°C 
after being chilled on ice for 30'. After heat shock cells were diluted in SOC medium and pre-
inoculated 45' at 37°C. 
After then, cells were plated on agar plates containing selective antibiotic and kept growing 





Plasmid library generation 
Double-stranded degenerated oligonucleotides generation 
Degenerated oligonucleotides mixtures have been synthetized as single strands by TIB 
molBiol. To obtain double stranded mixtures, oligos were incubated 40' at 72°C with Taq 
Polymerase (Promega) and an oligonucleotide complementary to the non-degenerated 3'end of 
oligos. The reaction product was isolated in Agarose gel and used for Gibson Assembly. 
Gibson Assembly 
400 ng of linearized vector (about 4x1010 molecules) and degenerated oligos in 1:25 ratio were 
incubated 1h at 60°C in a reaction mix containing dNTPs, 3' DNA exonuclease, DNA polymerase 
and Taq ligase (HiFi DNA assembly kit, New England Biolabs) 
High efficiency electrocompetent cells electroporation 
Electrocompetent cells were transformed using GenePulser (BioRad) set at 2.0 kV, 200 Ω and 
25 µF. 100 ng of plasmide (about 1010 molecules) were used. 
After electroporation cells have been diluted in SOC medium and pre-inoculated 1h at 37°C. 
Part of them was plated to verify transformation efficiency and the remaining part has been 
diluted in 1l and kept growing overnight until reaching 1 OD of density. 
Estraction of plasmid DNA 
Plasmid DNA was extracted from cells using Nucleobond extraction kit (Macherey-Nagel). For 
the entire library preparation, 3 columns were used under manufacturer's indications. After 




All animal procedures were approved by the internal committee for the protection of animals 
used for scientific purposes (OPBA) of the Ospedale policlinico San Martino and by the Italian 
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Ministry of Health according to the Italian Law D. lgs 26/2014 and the European Directive 
2010/63/EU of the European Parliament. In all the experiments were used the C57BL/6J and the 
NOD.CB17-Prkdcscid/J strains (hereinafter respectively referred as C57BL/6 and NOD/SCID) from 
Jackson Laboratory. 
For all surgery procedures, mice were anesthetized by a drug cocktail containing Metedomine 
0.5mg/Kg, Midazolam 5mg/kg and Fentanyl 0.005mg/kg, and awakened by mixture of 
Atipamezol 2.5mg/kg, Flumacenil 0.5mg/kg and Naloxon 1.2mg/kg. 
 
Intraventricolar injections 
In utero intraventricular injections were performed on anesthetized pregnant dams at the 
fourteenth day of gestation. Females were anesthetized and following laparotomy, uterine horns 
were exposed. Embryos were injected using a glass capillary needle within the telencephalic 
ventricles with approximately 2 μl of retroviral suspension containing 1% polybrene (Sigma) to 
facilitate cell infection and Fast green (Sigma) as contrast agent. After birth, injected animals 
were daily monitored and sacrificed at the appearance of neurologic symptoms. 
Resolbable suture was used before awakening the animals. 
 
Intracranic injection of tumoral cells 
Tumor cells were injected in deeply anesthetized adult C57/bl6 or NOD/SCID mice mounted 
on a stereotaxic apparatus. Up to 5 µl of cell suspension for each mouse, containing 30000 to 
50000 acutely dissociated cells, were injected using a Hamilton syringe (Bregma coordinates: AP, 
1.0 mm; L, 1.5 mm left and 2.5 mm below the skull surface). Animals were then monitored daily 
for the onset of neurologic symptoms. 
Dissection and dissociation of tumors 
Brains were explanted from mice and positioned under fluorescence stereomicroscope 
(Leica): tumor areas are recognizable by GFP expression, hyper vascularization and necrosis. 
36 
 
Tumor and surrounding areas were dissected and enzymatically digested with trypsin for 20' at 
37°C and then mechanically dissociated using a Pasteur pipette. If the percentage of GFP positive 
cells in the resulting population was less than 10%, cells were enriched by FACS sorting using a 
high recovery mask. 
NGS sequencing 
Ion Torrent Sequencing 
Plasmid or genomic DNA samples have been amplified by PCR using primers complementary 
to barcode flanking regions, and containing IonA and IonP1 adaptor sequences for Ion Torrent 
platform. PCRs were performed in a real-time thermocycler (Bio-Rad) in order to observe the 
reaction and stop it in exponential phase to avoid drifts that could lead to non-representative 
sampling. Amplicons have been purified from primers by agarose gel electrophoresis and purified 
using Qiagen Gel Extraction Kit. 
Sequencing libraries have been sequenced using Ion PGM machine (Thermo Fischer) and 314 
chips.  
Illumina Sequencing 
Genomic DNA samples have been amplified by PCR using primers complementary to barcode 
flanking regions, containing the first part of Illumina adaptor sequences and a sample-specific 
index sequence 6 nt long. Each sample was then identified by the couple of indexes present in 
the forward and in the reverse primer. Using 10 different forward primers and 8 different reverse 
primers I had the possibility to pool up to 80 samples in a single sequencing run. 
After the first PCR reaction, performed in a Bio-Rad real-time thermocycler and stopped in the 
exponential phase, each PCR reaction was individually diluted 1:30 and used as template for a 
second short PCR reaction, using primers containing the second part of Illumina adaptors and a 
second couple of sample-specific Indexes, chosen to coherently correspond to the first couple. 




Each sequencing was analyzed using "Biostrings" library of Bioconductor R package. Self-
developed scripts were used to align each read from fastQ files to the retroviral backbone region, 
and using the alignment coordinate it was possible to retrieve the barcode sequence from each 
single read. When present, the sample specific indexes were also retrieved and used to couple 
each barcode with its sample.  
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